GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Beijing Aosaikang Pharmaceutical Co 002755.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

12.73

+0.55%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Beijing Aosaikang Pharmaceutical Co

Its shares trade on Shenzhen under the ticker 002755.SZ. It has been listed since 15 May 2015. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.78bn and net income of CN¥236.6m. At that date it held total assets of CN¥4.52bn and shareholders' equity of CN¥3.22bn.

Beijing Aosaikang Pharmaceutical Co., Ltd. engages in the provision of engineering and geotechnical engineering services in the petrochemical and coal chemical industry. The company is headquartered in Beijing, Beijing. The company went IPO on 2015-05-15. The firm produces proton pump inhibitor injections through its subsidiary Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
15 May 2015
Employees
1,215

Leadership

Pay as last reported

  • Mr. Qingcai ChenChairman of the Board, since 2019CN¥1.9m
  • Mr. Tao HanChief Financial OfficerCN¥802,000
  • Mr. Jingfei MaGeneral Manager, Secretary of the Board, Director, since 2021CN¥900,000
  • Mr. Xiangfeng ChenDeputy General Manager, Director, since 2019CN¥1.0m
  • Ms. Xiaowen WangDirector
  • Ms. Suling ZhouDirector
  • Mr. Zaiwei ZongDirector
  • Mr. Baisheng JiangIndependent Director
  • Mr. Zhenxing LinIndependent Director
  • Mr. Peiqing LiuIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • The company employs 1215 full-time staff members in Beijing.
  • It produces proton pump inhibitor injections via a subsidiary.
  • It provides engineering services in the petrochemical industry.

Weaknesses

  • The company is headquartered in Beijing, China.
  • It went public on 15 May 2015.
  • The sector is classified as Health Care.

Opportunities

  • It offers geotechnical engineering services in coal chemical industry.
  • The subsidiary Jiangsu Aosaikang Pharmaceutical Co., Ltd. operates locally.
  • The firm engages in pharmaceutical production activities.

Threats

  • The industry is Pharmaceuticals, which faces market risks.
  • The country is CN, subject to local regulations.
  • The sector Health Care requires strict compliance standards.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.